It is playing catch-up with a rival Lp (a) targeting antisense drug from Novartis and development partner Akcea, called pelacarsen, which is already in a phase 3 trial called HORIZON with major ...

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies.

Welcome to the Money blog, Sky News' personal finance and consumer hub. Today: our weekly Cheap Eats feature, in which a top chef tells us his most controversial opinion. And good mortgage news ...

Existing firing schemes for the firing of three-phase SCR bridge rectifiers used for industrial applications employ equidistant firing pulses. Mostly they consist of six identical phase control ...